{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T10:10:24Z","timestamp":1760609424174},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T00:00:00Z","timestamp":1652227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T00:00:00Z","timestamp":1652227200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Data concerning the efficacy of SARS-CoV-2 vaccines in patients with non-oncological hematologic conditions are lacking. These include autoimmune cytopenias (autoimmune hemolytic anemia AIHA, immune thrombocytopenia ITP, and autoimmune neutropenia), and bone marrow failure syndromes (aplastic anemia, low risk myelodysplastic syndromes, and paroxysmal nocturnal hemoglobinuria). These conditions may relapse\/reactivate after COVID-19 infection and vaccine. Moreover, they are mainly handled with immunosuppressive drugs that may hamper the response to vaccine. In this study, we prospectively evaluated the rate of seroconversion after mRNA SARS-CoV-2 vaccines in patients with autoimmune cytopenias or bone marrow failure syndrome after 2\u2009\u00b1\u20091\u00a0months from the last vaccine dose. Overall, 149 patients were tested and 135 (91%) seroconverted. The highest proportion of non-responders was observed in Evans syndrome (association of ITP and AIHA) and warm AIHA patients (p\u2009=\u20090.001), in those with lower levels of baseline serum IgG (p\u2009=\u20090.008), and in patients on active therapy with steroids (p\u2009=\u20090.03) who also had lower anti-Spike titers. The latter were inversely related with age, and a positively with lymphocyte counts. Additionally, patients who had received rituximab within 12\u00a0months from vaccination showed higher rates of non-response (p\u2009=\u20090.03) as compared to those treated before. Contrarily, cyclosporine alone, complement inhibitors, and bone marrow stimulating agents had no detrimental effect on seroconversion. These data suggest maintaining high vigilance and adherence to preventive\/protective measures in this population since a proportion of cases may not respond or exhibit low anti-Spike titers.<\/jats:p>","DOI":"10.1038\/s41598-022-11857-7","type":"journal-article","created":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T15:03:21Z","timestamp":1652281401000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Seroconversion to mRNA SARS-CoV-2 vaccines in patients with autoimmune cytopenias and bone marrow failures"],"prefix":"10.1038","volume":"12","author":[{"given":"Bruno","family":"Fattizzo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Bortolotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juri Alessandro","family":"Giannotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dario","family":"Consonni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Cantoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilma","family":"Barcellini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,11]]},"reference":[{"issue":"8","key":"11857_CR1","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.ccell.2021.07.012","volume":"39","author":"LM Greenberger","year":"2021","unstructured":"Greenberger, L. M. et al. Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies. Cancer Cell 39(8), 1031\u20131033. https:\/\/doi.org\/10.1016\/j.ccell.2021.07.012 (2021) (Epub 2021 Jul 22).","journal-title":"Cancer Cell"},{"issue":"8","key":"11857_CR2","doi-asserted-by":"publisher","first-page":"e583","DOI":"10.1016\/S2352-3026(21)00169-1","volume":"8","author":"K Maneikis","year":"2021","unstructured":"Maneikis, K. et al. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: A national prospective cohort study. Lancet Haematol. 8(8), e583\u2013e592. https:\/\/doi.org\/10.1016\/S2352-3026(21)00169-1 (2021) (Epub 2021 Jul 2).","journal-title":"Lancet Haematol."},{"issue":"8","key":"11857_CR3","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41408-021-00534-z","volume":"11","author":"F Malard","year":"2021","unstructured":"Malard, F. et al. Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies. Blood Cancer J. 11(8), 142. https:\/\/doi.org\/10.1038\/s41408-021-00534-z (2021).","journal-title":"Blood Cancer J."},{"issue":"16","key":"11857_CR4","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1182\/bloodadvances.2021005094","volume":"5","author":"C Perry","year":"2021","unstructured":"Perry, C. et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma. Blood Adv. 5(16), 3053\u20133061. https:\/\/doi.org\/10.1182\/bloodadvances.2021005094 (2021).","journal-title":"Blood Adv."},{"issue":"8","key":"11857_CR5","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.ccell.2021.07.016","volume":"39","author":"S Ehmsen","year":"2021","unstructured":"Ehmsen, S. et al. Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer. Cancer Cell 39(8), 1034\u20131036. https:\/\/doi.org\/10.1016\/j.ccell.2021.07.016 (2021) (Epub 2021 Jul 27).","journal-title":"Cancer Cell"},{"issue":"8","key":"11857_CR6","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.ccell.2021.07.001","volume":"39","author":"EA Griffiths","year":"2021","unstructured":"Griffiths, E. A. & Segal, B. H. Immune responses to COVID-19 vaccines in patients with cancer: Promising results and a note of caution. Cancer Cell 39(8), 1045\u20131047. https:\/\/doi.org\/10.1016\/j.ccell.2021.07.001 (2021) (Epub 2021 Jul 3).","journal-title":"Cancer Cell"},{"key":"11857_CR7","doi-asserted-by":"publisher","first-page":"609198","DOI":"10.3389\/fimmu.2020.609198","volume":"11","author":"W Barcellini","year":"2021","unstructured":"Barcellini, W., Giannotta, J. A. & Fattizzo, B. Are patients with autoimmune cytopenias at higher risk of COVID-19 pneumonia? The experience of a reference center in northern Italy and review of the literature. Front. Immunol. 11, 609198. https:\/\/doi.org\/10.3389\/fimmu.2020.609198 (2021).","journal-title":"Front. Immunol."},{"issue":"9","key":"11857_CR8","doi-asserted-by":"publisher","first-page":"E344","DOI":"10.1002\/ajh.26262","volume":"96","author":"B Fattizzo","year":"2021","unstructured":"Fattizzo, B., Giannotta, J. A., Cecchi, N. & Barcellini, W. SARS-CoV-2 vaccination induces breakthrough hemolysis in paroxysmal nocturnal hemoglobinuria on complement inhibitor. Am. J. Hematol. 96(9), E344\u2013E346. https:\/\/doi.org\/10.1002\/ajh.26262 (2021) (Epub 2021 Jun 18).","journal-title":"Am. J. Hematol."},{"key":"11857_CR9","doi-asserted-by":"publisher","first-page":"791429","DOI":"10.3389\/fimmu.2021.791429","volume":"12","author":"B Fattizzo","year":"2021","unstructured":"Fattizzo, B., Pasquale, R., Bellani, V., Barcellini, W. & Kulasekararaj, A. G. Complement mediated hemolytic anemias in the COVID-19 era: Case series and review of the literature. Front. Immunol. 12, 791429. https:\/\/doi.org\/10.3389\/fimmu.2021.791429 (2021).","journal-title":"Front. Immunol."},{"issue":"5","key":"11857_CR10","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1111\/bjh.17558","volume":"194","author":"W Barcellini","year":"2021","unstructured":"Barcellini, W. et al. COVID-19 in patients with paroxysmal nocturnal haemoglobinuria: An Italian multicentre survey. Br. J. Haematol. 194(5), 854\u2013856. https:\/\/doi.org\/10.1111\/bjh.17558 (2021) (Epub 2021 May 25).","journal-title":"Br. J. Haematol."},{"issue":"11","key":"11857_CR11","doi-asserted-by":"publisher","first-page":"E413","DOI":"10.1002\/ajh.26345","volume":"96","author":"B Fattizzo","year":"2021","unstructured":"Fattizzo, B., Giannotta, J. A., Cecchi, N. & Barcellini, W. SARS-CoV-2 vaccination in patients with autoimmune cytopenias: The experience of a reference center. Am. J. Hematol. 96(11), E413\u2013E416. https:\/\/doi.org\/10.1002\/ajh.26345 (2021) (Epub 2021 Sep 16).","journal-title":"Am. J. Hematol."},{"key":"11857_CR12","doi-asserted-by":"publisher","first-page":"100648","DOI":"10.1016\/j.blre.2019.100648","volume":"41","author":"U J\u00e4ger","year":"2020","unstructured":"J\u00e4ger, U. et al. Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting. Blood Rev. 41, 100648. https:\/\/doi.org\/10.1016\/j.blre.2019.100648 (2020) (Epub 2019 Dec 5).","journal-title":"Blood Rev."},{"issue":"23","key":"11857_CR13","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","volume":"3","author":"C Neunert","year":"2019","unstructured":"Neunert, C. et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 3(23), 3829\u20133866. https:\/\/doi.org\/10.1182\/bloodadvances.2019000966 (2019) (Erratum in: Blood Adv. 2020;4(2):252).","journal-title":"Blood Adv."},{"issue":"2","key":"11857_CR14","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.annonc.2020.11.002","volume":"32","author":"P Fenaux","year":"2021","unstructured":"Fenaux, P. et al. Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 32(2), 142\u2013156. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.002 (2021) (Epub 2020 Nov 19).","journal-title":"Ann. Oncol."},{"issue":"2","key":"11857_CR15","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/bjh.13853","volume":"172","author":"SB Killick","year":"2016","unstructured":"Killick, S. B. et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br. J. Haematol. 172(2), 187\u2013207. https:\/\/doi.org\/10.1111\/bjh.13853 (2016) (Epub 2015 Nov 16, Erratum in: Br J Haematol. 2016 Nov;175(3):546).","journal-title":"Br. J. Haematol."},{"issue":"8","key":"11857_CR16","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.jiph.2021.07.005","volume":"14","author":"A Lombardi","year":"2021","unstructured":"Lombardi, A. et al. SARS-CoV-2 anti-spike antibody titres after vaccination with BNT162b2 in na\u00efve and previously infected individuals. J. Infect. Public Health. 14(8), 1120\u20131122. https:\/\/doi.org\/10.1016\/j.jiph.2021.07.005 (2021) (Epub 2021 Jul 17).","journal-title":"J. Infect. Public Health."},{"issue":"11","key":"11857_CR17","doi-asserted-by":"publisher","first-page":"e778","DOI":"10.1016\/S2665-9913(21)00222-8","volume":"3","author":"L Boekel","year":"2021","unstructured":"Boekel, L. et al. Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: A substudy of data from two prospective cohort studies. Lancet Rheumatol. 3(11), e778\u2013e788 (2021).","journal-title":"Lancet Rheumatol."},{"key":"11857_CR18","doi-asserted-by":"publisher","first-page":"102744","DOI":"10.1016\/j.jaut.2021.102744","volume":"125","author":"C Ferri","year":"2021","unstructured":"Ferri, C. et al. Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients\u2019 subgroups. J. Autoimmun. 125, 102744 (2021).","journal-title":"J. Autoimmun."},{"issue":"10","key":"11857_CR19","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1136\/annrheumdis-2021-220626","volume":"80","author":"M Prendecki","year":"2021","unstructured":"Prendecki, M. et al. Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression. Ann. Rheum. Dis. 80(10), 1322\u20131329 (2021).","journal-title":"Ann. Rheum. Dis."},{"issue":"9","key":"11857_CR20","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/j.vaccine.2022.01.040","volume":"40","author":"M Tanguay","year":"2022","unstructured":"Tanguay, M. et al. B-cell cytopenia and time to last B-cell-depleting therapy predict response to SARS-COV-2 vaccines in patients with lymphoproliferative disorders. Vaccine. 40(9), 1203\u20131207 (2022).","journal-title":"Vaccine."},{"key":"11857_CR21","doi-asserted-by":"crossref","unstructured":"Fattizzo, B. et al. Seroconversion to mRNA SARS-CoV-2 vaccines in hematologic patients. Front. Immunol. (2022) (in Press)","DOI":"10.3389\/fimmu.2022.852158"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11857-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11857-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11857-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T03:07:56Z","timestamp":1669345676000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11857-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,11]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["11857"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-11857-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,11]]},"assertion":[{"value":"31 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7743"}}